Theresa A. Deisher, Ph.D., graduated from Stanford University School of Medicine with a doctoral degree in molecular and cellular physiology. She has 47 issued patents and four discoveries in clinical trials. Dr. Deisher has extensive scientific and management experience in the commercial biotechnology field at Genentech, Repligen, ZymoGenetics, Immunex, and Amgen. Since 2008, she has led a team of innovative scientists at AVM Biotechnology who have developed AVM0703, a drug with a novel mechanism of action that mobilizes the body’s own natural immune cells to fight blood cancers, solid tumors, and infectious disease such as COVID-19 and influenza-mediated ARDS.